

REGENERON PHARMACEUTICALS INC

Form 8-K

November 13, 2007

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 13, 2007 (November 9, 2007)**

**REGENERON PHARMACEUTICALS, INC.**  
(Exact Name of Registrant as Specified in Charter)

**New York**

**000-19034**

**13-3444607**

(State or other jurisdiction of  
Incorporation)

(Commission File No.)

(IRS Employer Identification No.)

**777 Old Saw Mill River Road, Tarrytown, New York 10591-6707**

(Address of principal executive offices, including zip code)

**(914) 347-7000**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 9.01 Financial Statements and Exhibits

SIGNATURES

Exhibit Index

EX-99.1: AMENDED AND RESTATED BY-LAWS

---

**Table of Contents**

**Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.**

In order to comply with recent rules promulgated by the Nasdaq Stock Market LLC, the Board of Directors of Regeneron Pharmaceuticals, Inc. (the Company) on November 9, 2007, approved an amendment to Article V of the Company's By-Laws to authorize the Board to provide by resolution that some or all of the classes of stock of the Company be uncertified securities. On November 9, 2007, the Board of Directors of the Company adopted a resolution that provided that shares of the Company's common stock, par value \$.001 per share may be uncertificated.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Amended and Restated By-Laws of Regeneron Pharmaceuticals, Inc.

---

**Table of Contents**

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 13, 2007

REGENERON PHARMACEUTICALS, INC.

By: /s/ Stuart Kolinski

Name: Stuart Kolinski

Title: Senior Vice President and General  
Counsel

---

**Table of Contents**

Exhibit Index

Number	Description
99.1	Amended and Restated By-Laws of Regeneron Pharmaceuticals, Inc.